Cargando…

Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation

The treatment strategy in multiple myeloma (MM) is to get complete remission followed by high-dose chemotherapy and autologous Hematopoietic Stem Cell Transplantation (HSCT). Neoplastic Plasma Cells (NPCs) are CD45(−/dim), CD38(+high), CD138(+), CD19(−), and CD56(+high) in most cases. The descripti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dal Bó, Suzane, Pezzi, Annelise, Amorin, Bruna, Valim, Vanessa, Isabel Bittencourt, Rosane, Silla, Lucia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3705753/ https://www.ncbi.nlm.nih.gov/pubmed/23864957 http://dx.doi.org/10.1155/2013/847672

Ejemplares similares

Validation of the EBMT Risk Score for South Brazilian Patients Submitted to Allogeneic Hematopoietic Stem Cell Transplantation
por: Pitombeira, Beatriz Stela, et al.
Publicado: (2013)

Erratum to “DNMT3A Mutations in Patients with Acute Myeloid Leukemia in South Brazil”
por: Pezzi, Annelise, et al.
Publicado: (2014)

DNMT3A Mutations in Patients with Acute Myeloid Leukemia in South Brazil
por: Pezzi, Annelise, et al.
Publicado: (2012)

Donor characteristics and hematopoietic stem cell transplantation outcome: experience of a single center in Southern Brazil
por: Paz, Alessandra, et al.
Publicado: (2018)

Mesenchymal stem cell therapy and acute graft-versus-host disease: a review
por: Amorin, Bruna, et al.
Publicado: (2014)

Assessment of Regulatory T Cells in Childhood Immune Thrombocytopenic Purpura
por: Mazzucco, Karina L. M., et al.
Publicado: (2013)

Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma
por: Foureau, David, et al.
Publicado: (2021)

Standardizing Clinical Workflow for Assessing Minimal Residual Disease by Flow Cytometry in Multiple Myeloma
por: Foureau, David M., et al.
Publicado: (2023)

Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
por: Ikoma, Maura Rosane Valério, et al.
Publicado: (2015)

High Prevalence of Anemia in Children and Adult Women in an Urban Population in Southern Brazil
por: Silla, Lucia Mariano da Rocha, et al.
Publicado: (2013)

Impact of Minimal Residual Disease, Detected by Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Lymphoblastic Leukemia
por: Bar, Merav, et al.
Publicado: (2014)

Comparative analysis of minimal residual disease detection by multiparameter flow cytometry and enhanced ASO RQ-PCR in multiple myeloma
por: Silvennoinen, R, et al.
Publicado: (2014)

Cardiovascular risk and use of conicity index in patients submitted to autologous hematopoietic stem cell transplantation
por: de Morais, Suelyne Rodrigues, et al.
Publicado: (2018)

The expression of CD56 antigen is associated with poor prognosis in patients with acute myeloid leukemia
por: Alegretti, Ana Paula, et al.
Publicado: (2011)

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma
por: Rasche, L, et al.
Publicado: (2018)

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial
por: Oliva, Stefania, et al.
Publicado: (2021)

Comparison of Minimal Residual Disease Detection by Multiparameter Flow Cytometry, ASO-qPCR, Droplet Digital PCR, and Deep Sequencing in Patients with Multiple Myeloma Who Underwent Autologous Stem Cell Transplantation
por: Takamatsu, Hiroyuki
Publicado: (2017)

P908: FACTORS ASSOCIATED WITH THE CLINICAL PROGNOSTIC PERFORMANCE OF MINIMAL RESIDUAL DISEASE ASSESSMENT BY NEXT GENERATION FLOW CYTOMETRY IN MULTIPLE MYELOMA
por: Nandakumar, B., et al.
Publicado: (2022)

Clinical impact of systematic nutritional care in adults submitted to allogeneic hematopoietic stem cell transplantation
por: Sommacal, Heloisa Martins, et al.
Publicado: (2012)

Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma without Cryopreservation
por: Al-Anazi, Khalid Ahmed
Publicado: (2012)

Update on the Role of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tosi, P., et al.
Publicado: (2012)

Mobilization Strategies in Myeloma Patients Intended for Autologous Hematopoietic Cell Transplantation
por: Jantunen, Esa, et al.
Publicado: (2023)

Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation
por: Wirk, Baldeep, et al.
Publicado: (2013)

Impact of Minimal Residual Disease Detection by Next-Generation Flow Cytometry in Multiple Myeloma Patients with Sustained Complete Remission after Frontline Therapy
por: Terpos, Evangelos, et al.
Publicado: (2019)

Minimal residual disease in multiple myeloma: are we there yet?
por: Devarakonda, Srinivas, et al.
Publicado: (2020)

Minimal residual disease in multiple myeloma: current status
por: Ding, Hong, et al.
Publicado: (2021)

Drug resistance and minimal residual disease in multiple myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
por: Tuchman, S. A., et al.
Publicado: (2012)

Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients
por: FU, CHENGCHENG, et al.
Publicado: (2013)

Minimal residual disease by either flow cytometry or cytogenetics prior to an allogeneic hematopoietic stem cell transplant is associated with poor outcome in acute myeloid leukemia
por: Norkin, Maxim, et al.
Publicado: (2017)

Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation
por: Takamatsu, H., et al.
Publicado: (2017)

Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment
por: Liu, Jiahui, et al.
Publicado: (2023)

The utility of multiparametric flow cytometry for the detection of minimal residual disease in acute lymphoblastic leukemia
por: Cunha, Fernanda Gonçalves Pereira, et al.
Publicado: (2012)

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry
por: Ho, Caleb, et al.
Publicado: (2021)

Minimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
por: Nishihori, Taiga, et al.
Publicado: (2016)

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future
por: Medina-Herrera, Alejandro, et al.
Publicado: (2023)

Sequential, Autologous Hematopoietic Stem Cell Transplant Followed by Renal Transplant in Multiple Myeloma
por: Bhowmik, D., et al.
Publicado: (2017)

Prevalence and Significance of Sarcopenia in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation
por: Williams, Alexis, et al.
Publicado: (2020)

Tandem Autologous Hematopoietic Stem Cell Transplantation in Very Young Patients with Multiple Myeloma
por: Naithani, Rahul, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g4dcd3r0jj2fqb97f2er9g2l29